William m. Armstead, Ph.D.
Reasearch Professor, Department of Anesthesia and Critical Care
Member of the Graduate Groups in Neuroscience and Pharmacology
Member, Institute of Neurological Sciences, UPenn
Member, Cardiovascular Institute, UPenn
Dr. Armstead's research focuses on characterizing mechanisms important in the control of cerebral hemodynamics under physiologic and pathologic conditions such as traumatic brain injury (TBI), stroke, and cerebral hypoxia/ischemia, particularly in the newborn. Current projects focus on interactions between the NMDA receptor and plasminogen activators after TBI, optimizing the efficacy/toxicity ratio of tPA, the only FDA approved treatment for stroke and translational research concerning the roles of sex and age in outcome after pediatric TBI.
Armstead WM, Kiessling JW, Riley J, Kofke WA, Vavilala MS. Phenylephrine infusion
prevents impairment of ATP and Calcium sensitive K channel mediated cerebrovasodilation
after brain injury in female but aggravates impairment in male piglets through modulation
of ERK MAPK upregulation. J Neurotrauma, 28: 105-111, 2011.
Armstead WM, Kiessling JW, Cines DB, Higazi AAR. Glucagon protects against impaired
NMDA-mediated cerebrovasodilation and cerebral autoregulation during hypotension after
brain injury by activating cAMP protein kinase A and inhibiting upregulation of tPA.
J Neurotrauma 28: 451-457, 2011.
Armstead WM, Ganguly K, Riley J, Kiessling JW, Cines DB, Higazi AAR, Zaitsev S,
Muzykantov VR. RBC-coupled tPA prevents impairment of cerebral vasodilatory
responses through inhibition of JNK and potentiation of p38 MAPK after cerebral photo-
thrombosis in the newborn pig. Ped Crit Care Med 12:369-375, 2011.